Collplant Biotechnologies Ltd (CLGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 13, 2026 at 4:00 PM ET
Collplant Biotechnologies Ltd (CLGN) Competitors
The companies most similar to Collplant Biotechnologies are Pluri (PLUR), Celularity (CELU) and Biocardia (BCDA). By market cap, Collplant Biotechnologies ranks 9th of the 13 companies on this page; Plus Therapeutics (PSTV) is the largest at $26.64M.
Peer Comparison
CLGN's revenue growth of -39.7% is below the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Collplant Biotechnologies (CLGN) | $14.27M | N/A | 21.0x | 0.0% | N/A | -39.7% | 0.00% |
| Pluri Inc. (PLUR) | $15.09M | N/A | 8.7x | 0.0% | -650.8% | -15.8% | 0.00% |
| Celularity Inc (CELU) | $20.45M | N/A | 1.0x | -245.7% | N/A | -5.3% | 0.00% |
| Biocardia Inc (BCDA) | $12.58M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | $9.90M | N/A | 16.4x | 0.0% | -72.3% | -15.9% | 0.00% |
| Context Therapeutics Inc (CNTX) | $16.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Chemomab Therapeutics Ltd DRC (CMMB) | $12.31M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Seres Therapeutics Inc (MCRB) | $14.27M | N/A | 6.6x | 0.0% | N/A | 68.9% | 0.00% |
| Pasithea Therapeutics Corp (KTTA) | $17.44M | N/A | N/A | 0.0% | N/A | 1498.0% | 0.00% |
| Citius Pharmaceuticals Inc (CTXR) | $14.69M | N/A | 1.9x | 0.0% | -84.3% | 0.0% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Biovie Inc (BIVI) | $12.12M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Akari Therapeutics PLC (AKTX) | $15.54M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $14.89M | N/A | 4.3x | 0.0% | -367.6% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Collplant Biotechnologies, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Pluri Inc. (PLUR) | Pluri Inc. is an innovative biotechnology company at the forefront of regenerative medicine and immunotherapy... | PLUR competitors |
| Celularity Inc (CELU) | Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. | CELU competitors |
| Biocardia Inc (BCDA) | BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapies for cardiovascular disease. | BCDA competitors |
| CytoMed Therapeutics Limited Ordinary Shares (GDTC) | CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human... | |
| Context Therapeutics Inc (CNTX) | Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid... | CNTX competitors |
| Chemomab Therapeutics Ltd DRC (CMMB) | Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. | CMMB competitors |
| Seres Therapeutics Inc (MCRB) | Seres Therapeutics, Inc., a microbiome therapeutic platform company, is involved in the development of bacterial consortia that are designed to functionally... | MCRB competitors |
| Pasithea Therapeutics Corp (KTTA) | Pasithea Therapeutics Corp. The company is headquartered in Miami Beach, Florida. | KTTA competitors |
| Citius Pharmaceuticals Inc (CTXR) | Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets critical care products. | CTXR competitors |
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Biovie Inc (BIVI) | BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. | BIVI competitors |
| Akari Therapeutics PLC (AKTX) | Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory... | AKTX competitors |
Frequently Asked Questions About CLGN
Who are Collplant Biotechnologies' main competitors?
The companies most similar to Collplant Biotechnologies include Pluri (PLUR), Celularity (CELU), Biocardia (BCDA), CytoMed Therapeutics Limited Ordinary Shares (GDTC) and Context Therapeutics (CNTX), listed from the closest match.
Who is Collplant Biotechnologies' biggest competitor?
Plus Therapeutics (PSTV) is the largest of the similar companies at $26.64M; Pluri (PLUR) is the closest match by business profile, size, sector and industry.
How does CLGN stock compare with its competitors?
CLGN's P/S is 21.0x against a peer median of 4.3x; its net margin is 0.0% against a peer median of 0.0%.
Which of Collplant Biotechnologies' competitors pays a higher dividend?
Collplant Biotechnologies pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Collplant Biotechnologies bigger than its competitors?
No. Collplant Biotechnologies is 9th by market cap among the 13 companies on this page; the largest is Plus Therapeutics (PSTV) at $26.64M.
CLGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors